SecBot SecBot
PRESS-RELEASE ·Filed Apr 27, 2026

ORKA

Oruka Therapeutics, Inc.
BEARISH
Impact 6/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

Expect near-term price weakness due to dilution. Watch for pricing details in the prospectus supplement and any updates on use of proceeds. The stock may find support if proceeds are allocated to promising pipeline catalysts.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$73.99
T+0 close · Apr 27, 2026 · via day close
Latest settled
+24.27%
T+60 · $91.95
Vs SPY
+20.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 28 $73.99entry
  2. T+1 · 7mo ago −6.08%α −6.07% · $69.49
  3. T+5 · 7mo ago −10.18%α −11.87% · $66.46
  4. T+20 · 6mo ago −20.18%α −25.65% · $59.06
  5. T+60 · 4mo ago +24.27%α +20.28% · $91.95
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oruka Therapeutics announced a $500M underwritten public offering of common stock and pre-funded warrants, with an additional $75M option for underwriters. The proceeds will support its clinical-stage pipeline for psoriasis and inflammatory diseases. The offering represents roughly 15% dilution at current market cap, which is a negative signal for near-term stock price.

Key Financial Metrics

Deal Value
$500.0M

Key Facts

  • $500M underwritten public offering of common stock and pre-funded warrants
  • Underwriters have a 30-day option to purchase up to an additional $75M of shares
  • Leerink Partners, TD Cowen, Goldman Sachs, Stifel, and Guggenheim Securities are joint bookrunning managers
  • Shelf registration statement (Form S-3) became effective on April 10, 2026
  • Offering size is approximately 14.7% of the $3.4B market cap

Financial Impact

Approximately $500M raised (up to $575M with greenshoe), diluting existing shareholders by ~14.7% at current market cap

dilutionshare count

Risk Factors

  • Dilution of existing shareholders
  • Offering may not close if market conditions deteriorate
  • Clinical-stage biotech carries inherent pipeline risk
  • Potential for further offerings as cash needs increase

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3282035

Track record

40 reports on ORKA

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 10 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
  3. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
  4. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  6. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  7. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
  8. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  9. Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
Showing 10 of 40

US Market Status

Market Closed · Opens in 9h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026